RAYMOND B. WEISS, M.D.; VINCENT T. DeVITA Jr., M.D.
In the 1970s chemotherapy has been successfully incorporated into curative primary treatment programs for various adult malignancies so that it is no longer solely palliative treatment for advanced disease. For at least three malignancies and tentatively a fourth (breast and colon carcinoma, osteosarcoma, and melanoma), certain groups of patients have had longer disease-free survival produced by the use of chemotherapy after surgical removal of the primary lesion. The potential impact on cancer mortality from these treatment results is obvious. We review here the fundamental laboratory concepts that have led to human trial of multimodal primary therapy regimens. Data from numerous clinical trials are analyzed, with delineation of the problems encountered in the interpretation of their results.
WEISS RB, DeVITA VT. Multimodal Primary Cancer Treatment (Adjuvant Chemotherapy): Current Results and Future Prospects. Ann Intern Med. ;91:251–260. doi: 10.7326/0003-4819-91-2-251
Download citation file:
Published: Ann Intern Med. 1979;91(2):251-260.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use